



# Detection of 16S Ribosomal RNA Methylation in Extended-Spectrum $\beta$ -lactamase-Producing *Klebsiella Pneumoniae* Clinical Isolates from Baghdad Hospitals

Israa M. S. AL-Kadmy<sup>1</sup>, Hadeel K. Musaffer<sup>1</sup>, Marwah Hasan Abd Ali<sup>2</sup>, Sawsan Sajid<sup>1</sup>

<sup>1</sup> Department of Biology, College of Science ,AL –Mustansiriya University

<sup>2</sup> National Center of Hematology, AL–Mustansiriya University

Received: December 15, 2014 / Accepted: February 18, 2015

**Abstract:** Fifty-eight Clinical isolates of *Klebsiella pneumoniae* were collected from patients at Al-Kindeg teaching hospital, Al-Kadhymia teaching hospital, Ibn-Albalady hospital and Al-Imam-Ali hospital in Baghdad from Urinary tract infection (UTI) patient. These isolates were diagnosed using different morphological and biochemical test followed by the complementary API 20E, isolates all screened for antibiotic resistance by rapid detection of  $\beta$ -lactamases production method and their minimum inhibitory concentrations(MICs) were conducted by polymerase chain reaction assay. Detection of *bla*<sub>CTX-M</sub> gene was performed and highly resistant isolates (n=17) were selected to determine aminoglycoside resistance mediated by methylation 16S rRNA that combined with the detection of *bla*<sub>CTX-M</sub> gene responsible for Extended Spectrum  $\beta$ -lactamase (ES $\beta$ LS) production. Seven 16S rRNA methylase genes were amplified, the *ArmA*, *RmtA*, *RmtB*, *RmtC*, *RmtD*, *RmtF* and *npmA* beside amplifying *bla*<sub>CTX-M</sub> gene. This study explained the physically link between *bla*<sub>CTX-M</sub> gene (ES $\beta$ LS) production among *Klebsiella pneumoniae* in correlation with 16S rRNA methylation.

**Key words:** *Klebsiella pneumoniae*, ES $\beta$ LS, *bla*<sub>CTX-M</sub> gene, 16 rRNA methylation genes.

**Corresponding author:** should be addressed (Email: israaalkadmy@gmail.com)

## Introduction

Aminoglycosides, along with  $\beta$ -lactams, is currently one of the key classes of antimicrobial agents in the treatment of broad range of life-threatening infections caused by Gram-negative bacteria. Mechanisms of resistance to aminoglycosides include enzymatic modification of the drugs, modification of the aminoglycoside-binding site, decreased permeability across the bacterial outer membranes, and augmented efflux. Among them, production of acquired 16S rRNA methyltransferase is the most worrisome since it inhibited the activity

of all aminoglycosides (1). In Iraq, aminoglycosides were commonly used for treating severe infections caused by Gram-negative bacteria. As a result, multiple resistance determinants to these antimicrobial agents have emerged in various pathogenic microbes. Post-transcriptional methylation of the 16SrRNA has been reported, and these results in high-level resistance to aminoglycoside antibiotics (2). At present, ten 16S rRNA methylase genes have been identified, including *armA*, *rmtA*, *rmtB*, *rmtC*, *rmtD*, *rmtE*, *rmtF*, *rmtG*, *rmtH*, and

*npmA*, which are capable of conferring high levels of resistance to most clinically important aminoglycosides, including amikacin, gentamicin, kanamycin, and tobramycin. (1, 2, 3,4, 5,6,7,8, 9).

*RmtB* and *ArmA* are the most frequently identified methylases in Enterobacteriaceae isolated in East Asia, Europe, and South America. (10, 11,12,13,14). The six methylase enzymes expressed from the six genes have been described to be carried on plasmid and the pathogenic bacteria producing such enzymes have the ability to resist all aminoglycoside group. (11,15).

Associations between 16S rRNA methylase and extended-spectrum  $\beta$ -lactamase (ES $\beta$ Ls) production specially *bla<sub>CTX-M</sub>* group have been reported (11,14,15).

The aim of this study was to identify the prevalence of 16S rRNA methylase genes (*ArmA*, *RmtA*, *RmtB*, *RmtC*, *RmtD*, *RmtF* and *NpmA*) among ES $\beta$ L-producing *K. pneumoniae* isolates harbouring *bla<sub>CTX-M</sub>* obtained from patients presented with urinary tract infection (UTI).

## Materials and Methods

### Clinical Background

Fifty-eight clinical isolates of *Klebsiella pneumoniae* were isolated from patients at Al-Kindey teaching hospital, Al-Kadhymia teaching hospital, Ibn-Albalady hospital and Alemam-Ali hospital in Baghdad during a period between July 2011 and December 2011. They were obtained from midstream urine from patients suffering from (UTI). Bacterial diagnosis including morphological and biochemical tests

were done according to Atlas *et al.* (16) followed by the complementary API 20E test.

### Rapid Detection of $\beta$ -lactamases Production

The detection of  $\beta$ -lactamases production was performed using Rapid ES $\beta$ L detection kit (MAST Group, UK). This kit includes four tests: preliminary screening kit, Metallo- $\beta$ -lactamases, ES $\beta$ Ls confirmation and AmpC detection. The test was performed according to the procedure suggested by the manufacturing company: bacterial isolates were cultured on Muller Hinton agar medium with cefotaxime 30 $\mu$ g disc. The resisted isolates were submitted to ES $\beta$ Ls production test. One drop of test substrate (approximately 20 $\mu$ l) was dispensed onto the filter pad of the strip. The test substrate was added to the strip immediately before testing. Using a loop, one colony was picked up and spread on the filter pad of the test strip any change in color observed around the streaked line was considered a positive result. The test strip was observed after 2 to 15 minutes at room temperature, and the result was read after 15 minutes.

### Antibiotics Susceptibility Assay

All isolates were tested for MIC according to the CLSI (17) two fold agar dilution method were used (18,19), using four types of aminoglycoside antibiotic including: amikacin, kanamycin, gentamicin, paromomycin. *Escherichia coli* ATCC 25922 were used as quality control strain(Central Public Health Laboratory, Baghdad).

### Detection of Methylase and ESβLs Genes Using PCR

Plasmid DNA was extracted according to alkaline lysis method Crosa *et al.* (20) from overnight bacterial growth. The plasmid DNA was used as a DNA template for the PCR technique. The *armA*, *rmtA*, *rmtB*, *armC*, *rmtD*, *rmtF*,

*npmA* and *bla<sub>CTX-M</sub>* genes were detected by PCR using specific primers listed in table 1. PCR products were electrophoresed in 1.5% agarose gel and visualized under UV light. (Master Mix and 100 bp DNA molecular ladder which used in this study from KAPA(south Africa))(21).

**Table 1: Primers for detection of 16S rRNA methylation genes**

PCR target	Primer Name	Sequence (5'→3')	Amplicon size, base pairs	Reference
<i>bla<sub>CTX-M</sub></i>	<i>CTX-M-F</i> <i>CTX-M-R</i>	CGCTTTGCGATGTGCAG ACCGCGATATCGTTGGT	550	(37)
<i>RmtA</i>	<i>rmtA-F</i> <i>rmtA-R</i>	CTAGCGTCC ATCCTTTCCTC TTGCTTCCA TGCCCTTGCC	635	(34)
<i>RmtB</i>	<i>rmtB-F</i> <i>rmtB-R</i>	CCC AAA CAG ACC GTA GAGGC CTC AAA CTC GGC GGG CAAGC	584	(15)
<i>RmtC</i>	<i>rmtC-F</i> <i>rmtC-R</i>	CGA AGA AGT AAC AGC CAA AG ATC CCA ACA TCT CTC CCA CT	711	(4)
<i>RmtD</i>	<i>rmtD-F</i> <i>rmtD-R</i>	TCAAAAAGGAAAAGGACGTG CGATGCCGACGATCCATTC	500	(38)
<i>RmtF</i>	<i>rmtF -F</i> <i>rmtF -R</i>	GCGATACAGAAAACCGAAGG GGCAGGAGCTTCATCAGAA	453	(39)
<i>ArmA</i>	<i>armA-F</i> <i>armA-R</i>	CCGAAATGACAGTTCCTATC GAAAATGAGTGCCTTGGAGG	846	(40)
<i>NpmA</i>	<i>npmA-F</i> <i>npmA-R</i>	CTCAAAGGAACAAAGACGG GAAACATGGCCAGAAACTC	641	(38)

### Results

A total 58 of *Klebsiella pneumoniae* clinical isolates, were collected from Baghdad hospitals, have been studied. At first, the resistance mechanisms are identified by using of specific inhibitors on the color-coded test strips i.e. ESβL (Clavulanic Acid), MβL (EDTA and Mercaptoacetic Acid) and AmpC (Boronic Acid). It is easy to perform highly specific, different types of enzymes could be detected in the same

run. The findings from antimicrobial tests showed that *bla<sub>CTX-M</sub>* -positive isolates were revealed 17(100%) resistance to ESβLs, 8(47%) were resistance to MβL and 7(41.1%) resistance for AmpC of a total of 17 isolates. Whereas *bla<sub>CTX-M</sub>* -negative revealed 36(100%) were resistance to ESβL, 27(75%) and 3(8.3%) were resistance for MβL and AmpC respectively Table (2). Figure 1 depicts


the amplified *bla<sub>CTX-M</sub>* gene in *K. pneumoniae* isolates. This study has also revealed that isolates were aminoglycoside resistant to commercially aminoglycoside antibiotic the percentage of resistance were 17(100%) to Amikacin, Gentamicin, Kanamycin and Paromomycin by phenotypic confirmatory test. Whereas *bla<sub>CTX-M</sub>* -negative isolates their

resistance were between susceptible, intermediate and resistant to Amikacin, Gentamicin, Kanamycin and Paromomycin (Table 3). This study showed that all *bla<sub>CTX-M</sub>* negative isolates were sensitive to amikacin therefore; the amikacin antibiotic was the best drug of choice for *K. pneumoniae*.

**Table 2: Frequency of ESBLs-producing strains and susceptibility pattern**

β-lactemase type	<i>bla<sub>CTX-M</sub></i> -positive (n = 17)		<i>bla<sub>CTX-M</sub></i> -negative (n = 36)	
	Resistant n (%)	Susceptible n (%)	Resistant n (%)	Susceptible n (%)
ESBLs	17(100)	0	36(100)	0
MBL	8(47)	9(52.9)	27(75)	9(25)
AmpC	7(41.1)	10(58.8)	3(8.3)	33(91.7)

n= number



**Figure 1: Gel electrophoresis (1% agarose, 7 V/cm for 90min) of *bla<sub>CTX-M</sub>* gene in *K. pneumoniae* isolates using plasmid DNA as a template. lane M :100 bp DNA ladder , lanes (3,5,8,9,10,12) positive results for *bla<sub>CTX-M</sub>* gene with 550bp amplicon**

All the 17 resistant isolates were screened by PCR for the detection of

16S rRNA methylase-encoding genes (*armA*, *rmtA*, *rmtB*, *rmtC*, *rmtD*, *rmtF*)

and *npmA*). High levels of resistance to aminoglycosides conferred by plasmid-mediated mechanisms corresponding to 16S rRNA methylation, six genes (*armA*, *rmtA*, *rmtB*, *rmtC*, *rmtD*, *rmtF* and *npmA*) have been shown in figure 2. The MICs results for four aminoglycoside antibiotics (Amikacin, kanamycin, Gentamicin and Paromomycin) were shown (100%)

resistance. Isolates was characterized as resistant in comparison with CLSI (17). All the 17 *K. pneumoniae* isolates revealed resistance to Gentamicin (MIC ranged between 128-1024 µg /ml), Kanamycin (MIC ranged from 256-1024 µg /ml), Paromomycin (MIC ranged from 512-1024µg /ml) and Amikacin when (MIC ranged from 64-256 µg /ml) Table (4).

**Table 3: Frequency of aminoglycoside resistance strains and susceptibility pattern to aminoglycoside antibiotic**

Aminoglycoside	<i>bla<sub>CTX-M</sub></i> -positive (n = 17)			<i>bla<sub>CTX-M</sub></i> -negative (n = 36)		
	Resistant n (%)	Susceptible n (%)	Intermediate n (%)	Resistant n (%)	Susceptible n (%)	Intermediate n (%)
AMK	17(100)	0	0	0	30(83.3)	6(16.7)
GEN	17(100)	0	0	35(97.2)	0	1(2.77)
KAN	17(100)	0	0	34(94.4)	0	2(5.5)
PMR	17(100)	0	0	34(94.4)	0	2(5.5)

**R**, resistant; **I**, intermediate; **S**, sensitive. **AK**:amikacin, **GN**:gentamicin, **K**:kanamycin, **P**: paromomycin

**Table 4: MICs of antibiotics for clinical isolates producing 16S rRNA methylases**

Clinical isolate	16S rRNA methylase or/and ESBLs	MIC ( $\mu\text{g/ml}$ )			
		AMK $\geq 64$	GEN $\geq 16$	KAN $\geq 64$	PMR $\geq 16$
<i>K. pneumonia</i> 3	<i>bla</i> <sub>CTX-M</sub> and <i>npmA</i>	128	512	1024	1024
<i>K. pneumonia</i> 5	<i>bla</i> <sub>CTX-M</sub>	128	512	256	512
<i>K. pneumonia</i> 8	<i>bla</i> <sub>CTX-M</sub> and <i>rmtB</i>	128	512	256	512
<i>K. pneumonia</i> 9	<i>bla</i> <sub>CTX-M</sub> , <i>rmtC</i> , <i>rmtD</i> and <i>rmtF</i>	128	1024	1024	1024
<i>K. pneumonia</i> 10	<i>bla</i> <sub>CTX-M</sub>	128	256	512	512
<i>K. pneumonia</i> 12	<i>bla</i> <sub>CTX-M</sub> , <i>rmtD</i> and <i>npmA</i>	128	512	512	512
<i>K. pneumonia</i> 17	<i>bla</i> <sub>CTX-M</sub>	128	512	512	1024
<i>K. pneumonia</i> 18	<i>bla</i> <sub>CTX-M</sub> , <i>rmtC</i> , <i>armA</i> and <i>npmA</i>	128	1024	1024	512
<i>K. pneumonia</i> 23	<i>bla</i> <sub>CTX-M</sub> and <i>rmtB</i>	128	512	256	512
<i>K. pneumonia</i> 24	<i>bla</i> <sub>CTX-M</sub>	128	1024	1024	1024
<i>K. pneumonia</i> 28	<i>bla</i> <sub>CTX-M</sub> , <i>rmtD</i> and <i>armA</i>	128	1024	512	512
<i>K. pneumonia</i> 32	<i>bla</i> <sub>CTX-M</sub> , <i>armA</i>	64	256	512	1024
<i>K. pneumonia</i> 35	<i>bla</i> <sub>CTX-M</sub>	128	1024	1024	1024
<i>K. pneumonia</i> 36	<i>bla</i> <sub>CTX-M</sub> , <i>rmtC</i> and <i>npmA</i>	256	1024	1024	1024
<i>K. pneumonia</i> 39	<i>bla</i> <sub>CTX-M</sub> , <i>armA</i> and <i>npmA</i>	256	1024	512	1024
<i>K. pneumonia</i> 40	<i>bla</i> <sub>CTX-M</sub> , <i>rmtC</i> , <i>armA</i> and <i>rmtA</i>	128	1024	1024	1024
<i>K. pneumonia</i> 51	<i>bla</i> <sub>CTX-M</sub> and <i>armA</i>	256	1024	1024	1024

**Arm**, Antibiotic-resistant marker abbreviations: **AMK**, amikacin; **GEN**, gentamicin; **KAN**, kanamycin; **PMR**; paromomycin

A total of 17 ES $\beta$ L-producing *K. pneumoniae* clinical isolates harbored *bla*<sub>CTX-M</sub> gene, have been studied. All 17 isolates (100%) were resistant to aminoglycosides, screened by PCR for detection of 16S rRNA methylase-encoding genes (*armA*, *rmtA*, *rmtB*, *rmtC*, *rmtD*, *rmtF* and *npmA*). Surprisingly, only five isolates (3, 8, 23, 32, 51) have single gene of the 16S rRNA methylation genes combined with the presence of *bla*<sub>CTX-M</sub> gene, whereas six isolates have two genes of the 16S rRNA methylation genes (12,

18, 28, 36, 39, 40), and one isolate have three genes.

In addition, five isolates (5, 10, 17, 24, 35) were resistant to aminoglycoside but were negative for 16sRNA methylation genes.

### Discussion

We aimed to study the clinical epidemiology of these emerging co-resistant isolates. The prevalence of antimicrobial resistance among microorganisms that cause UTI is increasing worldwide problem and a

major factor in selecting antibiotics for treatment (22). The result comparatively resemble literature available. Co-resistance with  $\beta$ -lactams are frequently seen in ES $\beta$ L-producing gram negative bacteria particularly to aminoglycosides, beside that genes encoding ES $\beta$ LS are typically carried on the same self-transferable plasmids that often carry other determinants of antibiotic resistance (23,24). The organisms that produce 16SrRNA methylase are often multidrug resistant, especially against broad-spectrum  $\beta$ -lactams via production of ES $\beta$ LS or metallo- $\beta$ -lactamases. 2-tiered approach, consisting of phenotypic tests followed by PCR confirmation is recommended for detection of 16SrRNA methylase-mediated resistance.

From noticing the results of *K. pneumoniae* isolates, it's clear that the high-level of resistance (100%) was toward Amikacin, gentamicin, kanamycin and paromomycin when the MIC of some isolates reached 1024  $\mu$ g/ml (gentamicin, kanamycin and paromomycin) while the break point for these antibiotic is only 16  $\mu$ g/ml except for kanamycin which is 64  $\mu$ g/ml. It could be said that the best activity was to amikacin when the highest titer of MIC was 256  $\mu$ g/ml as a maximum rate for some isolates while the break point for this antibiotic is 64  $\mu$ g/ml.

The literature showed the values of MIC for gentamicin against *E.coli* isolates were 0.5-256  $\mu$ g/ml, these values are much lower than Risberg findings, (25) while Yamane *et al.* (26) reported that the MIC values reached to 1024  $\mu$ g/ml, thus it agreed with this study. For paromomycin MIC was between 32-1024  $\mu$ g/ml, the result of this study coincides with the results of

Fritsche *et al.* (27). In Brazil the MIC for Amikacin was (16-128)  $\mu$ g/ml and 32-256  $\mu$ g/ml by Fritsche *et al.* (27) and Gonza'les-Zorn *et al.* (28)

The range of MIC values for kanamycin and gentamicin were between 32-1024  $\mu$ g/ml and 16-1024  $\mu$ g/ml respectively which is coincide with the current study (29). Gad *et al.* (29) and Lim *et al.* (30) they reported that the rang of MIC to amikacin was between (64-128)  $\mu$ g/ml which is convenient with the current study.

All kind of methylation genes were detected in the local *K. pneumoniae* isolates. One of the interesting results in the current study is that one isolates of *K. pneumoniae* no. 9 harbored the three-methylation genes alongside with *bla*<sub>CTX-M</sub> gene table 4. Only one methylation gene appeared in five isolates (no.3, 8, 23, 32, 51) in addition to *bla*<sub>CTX-M</sub> gene. In addition there are five isolates harbourd only *bla*<sub>CTX-M</sub> gene because the resistance for aminoglycoside may be related to the mutation in 23S rRNA, efflux mechanisms, aminoglycoside modifying enzymes (AMEs) and impermeability of the cell wall may cause reduced susceptibility to aminoglycosides and the most prevalent was efflux mechanisms according to Gallego and Towner (31), Nemec *et al.* (32), Shaw *et al.* (33). In this study, it seems to be an association between ES $\beta$ L-coding genes and 16S rRNA methylases is taken a place as it is summarized in table (4) which shows the correlation between *bla*<sub>CTX-M</sub> gene and 16S rRNA methylase genes, since these genes are sometimes located on the same conjugative plasmid (34). Other finding which is fixed in the current study, that two or more 16S rRNA methylation genes were located on a same plasmid

belonging to *bla<sub>CTX-M</sub>* gene (*K. pneumoniae* no.12, 18, 28, 36, 39, and 40), especially *K. pneumoniae* no.9 that contained three 16S rRNA methylase genes and *bla<sub>CTX-M</sub>* gene.

The responsible genes are mostly located on transposons within transferable plasmids, which provides them with the potential to spread horizontally and may in part explain the already worldwide distribution of this resistance mechanism, some of these isolates have been found to co-produce ES $\beta$ L or M $\beta$ L, contributing to their multidrug-resistant phenotypes. (4,24,35) This study underlines the co-association of 16S rRNA methylase and ES $\beta$ L-encoding genes linked together resulting in the multidrug-resistant for

both of *K. pneumoniae*, which is considered the first report in Iraq and may become a clinical problem. Worryingly, an increase in the prevalence of ES $\beta$ L, led to the prevalence of aminoglycoside resistance is likely to increase in the coming years. In Poland *K. pneumoniae* epidemic strain that coproduced carbapenemase and 16S rRNA methylase ArmA has emerged were found to carry the *bla<sub>KPC-2</sub>* and *armA* genes on plasmids (36). Acquired M $\beta$ L genes are located on integron that reside on mobile genetic elements such as plasmids or transposons, thus, enabling widespread dissemination. (35)




Figure 2: PCR amplification of *rmtF*, *armA*, *npmA*, *rmtA*, *rmtB* and *rmtC* genes

## References

1. Wachino, J. and Arakawa, Y. (2012). Exogenously acquired 16S rRNA methyltransferases found in aminoglycoside-resistant pathogenic Gram-negative bacteria: an update. *Drug. Resist. Updat.*, 15:33–148.
2. Galim, M.; Courvalin, P. and Lambert, T. (2003). Plasmid-mediated high-level Resistance to aminoglycosides in Enterobacteriaceae due to 16SrRNA methylation. *Antimicrob. Agents Chemother.*, 47:2565–2571.



3. Yokoyama, K.; Doi, Y.; Yamane, K.; Kurokawa, H.; Shibata, N. and Shibayama, K. (2003). Acquisition of 16S rRNA methylase gene in *Pseudomonas aeruginosa*. *Lancet*, 362:1888–1893.
4. Doi, Y. and Arakawa, Y. (2007). 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides. *Clin. Infect. Dis.*, 45:88–94.
5. Wachino, J.; Shibayama, K.; Kurokawa, H.; Kimura, K.; Yamane, K. and Suzuki, S. (2007). Novel plasmid-mediated 16S rRNA methyltransferase, NpmA, found in a clinically isolated *Escherichia coli* strain resistant to structurally diverse aminoglycosides. *Antimicrob. Agents Chemother.*, 51:4401–4409.
6. Davis, M.A.; Baker, K.N.; Orfe, L.H.; Shah, D.H.; Besser, T.E. and Call, D.R. (2010). Discovery of a gene conferring multiple-aminoglycoside resistance in *Escherichia coli*. *Antimicrob. Agents Chemother.*, 54:2666–2669.
7. Galim, M.; Courvalin, P. and Lambert, T. (2012). RmtF, a new member of the aminoglycoside resistance 16S rRNA N7 G1405 methyltransferase family. *Antimicrob. Agents Chemother.*, 56:3960–3962.
8. Bueno, M.F.; Francisco, G.R.; O'Hara, J.A.; de Oliveira Garcia, D. and Doi, Y. (2013). Co-production of 16S ribosomal RNA methyltransferase RmtD and RmtG with KPC-2 and CTX-M-group ESBLs in *Klebsiella pneumoniae*. *Antimicrob. Agents Chemother.*, 53:2397–2400.
9. O'Hara, J.A.; McGann, P.; Snesrud, E.C.; Clifford, R.J.; Waterman, P.E. and Lesho, E.P. (2013). Novel 16S ribosomal RNA methyltransferase RmtH produced by *Klebsiella pneumoniae* associated with war-related trauma. *Antimicrob. Agents Chemother.*, 2013:57:2413–2416.
10. Yan, J.J.; Wu, J.J.; Ko, W.C.; Tsai, S.H.; Chuang, C.L. and Wu, H.M. (2004). Plasmid-mediated 16S rRNA methylases conferring high-level aminoglycoside resistance in *Escherichia coli* and *Klebsiella pneumoniae* isolates from two Taiwanese hospitals. *J. Antimicrob. Chemother.*, 54:1007–1012.
11. Bogaerts, P.; Galimand, M.; Bauraing, C.; Deplano, A.; Vanhoof, R. and De Mendonca, R. (2007). Emergence of ArmA and RmtB aminoglycoside resistance 16S rRNA methylases in Belgium. *J. Antimicrob. Chemother.*, 59:459–464.
12. Berçot, B.; Poirel, L. and Nordmann, P. (2008). Plasmid-mediated 16S rRNA methylases among extended-spectrum beta lactamase-producing Enterobacteriaceae isolates. *Antimicrob. Agents Chemother.*, 52:4526–4527.
13. Kang, H.Y.; Kim, J.; Seol, S.Y.; Lee, Y.C.; Lee, J.C. and Cho, D.T. (2009). Characterization of conjugative plasmids carrying antibiotic resistance genes encoding 16S rRNA methylase, extended-spectrum beta lactamase, and/or plasmid-mediated AmpC beta-lactamase. *J. Microbiol.*, 47:68–75.
14. Yu, F.Y.; Yao, D.; Pan, J.Y.; Chen, C.; Qin, Z.Q. and Parsons, C. (2010). High prevalence of plasmid-mediated 16S rRNA methylase gene rmtB among *Escherichia coli* clinical isolates from a Chinese teaching hospital. *BMC. Infect. Dis.*, 10:184.
15. Lee, H.; Yong, D.; Yum, J.H.; Roh, K.H.; Lee, K.; Yamane, K.; Arakawa, Y. and Chong, Y. (2006). Dissemination of 16S rRNA methylase-mediated highly amikacin resistant isolates of *Klebsiella pneumoniae* and *Acinetobacter baumannii* in Korea. *Diagn Microbiol Infect. Dis.*, 53:305–312.
16. Atlas, R.M.; Brown, A.E. and Parks, L.C. (1995). *Laboratory manual of experimental microbiology*. 1<sup>st</sup> ed Mosby, St. Louis, U.S.A.
17. CLSI, (2013). (Clinical and Laboratory Standards Institute). Performance standard for antimicrobial susceptibility testing; Twenty-Third informational supplement. M100-S23(1).
18. Andrews, J.M. (2001). Determination of minimum inhibitory concentrations. *J. Antimicrob. Chemother.*, 48:5–16 21.
19. Wiegand, I.; Hilpert, K. and Hancock, R.E. (2008). Agar and Broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. *Nat. Protoc.*, 3:163–175.
20. Crosa, J.H.; Tolmasek, M.E.; Actis, L.A. and Falkow, S. (1994). *Plasmids: Methods for general and molecular bacteriology*. American Society for Microbiology, Washington DC, 365–386.
21. Sambrook, J. and Russell, D.W. (2001). *Molecular Cloning: In: A Laboratory Manual* Cold Spring Harbor, New York, USA, Cold Spring Harbor Laboratory Press.

22. Wassenaar, T.M. and Newell, D.G. (2000). Genotyping of *Campylobacter* spp. *Appl Environ. Microbiol.*, 66:1-9.
23. Kaleem, F.; Usman, J.; Hassan, A. and Khan, A. (2010). Frequency and susceptibility pattern of metallo-beta-lactamase producers in a hospital in Pakistan. *J. Infect. Dev. Ctries.*, 4:810-813.
24. Habeeb, M.A.; Haque, A.; Nematzadeh, S.; Iversen, A. and Giske, C.G. (2013). Prevalence of 16S rRNA methylase RmtB among CTX-M extended-spectrum  $\beta$ -lactamase-producing *Klebsiella pneumoniae* from Islamabad, Pakistan. *Int. J. Antimicrob. Agents*, 41:524-6.
25. Risberg, K. (2010) Aminoglycoside resistance mechanisms in Enterobacteriaceae M. Sc. Thesis, Department of Pharmacy, Faculty of Medicine. University of Tromsø. Norway.
26. Yamane, K.; Wachino, J.; Suzuki, S.; Shibata, N.; Kato, H. and Shibayama, K. (2007). 16S Rna Methylase-producing, Gram-negative Pathogens, *Japan. Emerg. Infect. Dis.*, 13:642-646.
27. Fritsche, T.R.; Castanheira, M.; Miller, G.H.; Jones, R.N. and Armstrong, E.S. (2008). Detection of Methyltransferases Conferring High-Level Resistance to Aminoglycosides in Enterobacteriaceae from Europe, North America, and Latin America. *Antimicrob. Agents Chemother.*, 52:1843-1845.
28. Gonza'les-Zorn, B.; Teshager, T.; Casas, M.; Porrero, M.C.; Moreno, M.A. and Courvalin, P. (2005). *armA* and aminoglycoside resistance in *Escherichia coli*. *Emerg. Infect. Dis.*, 11:954-956.
29. Gad, G.F.; Mohamed, H.A. and Ashour, H.M. (2011). Aminoglycosides Resistance Rates, Phenotypes, and Mechanisms of Gram-Negative Bacteria from Infected Patients in Upper Egypt. *PLoS. One*, 1-7.
30. Lim, T.; Lee, W.; Tan, T.; Sasikala, S.; Teo, J. and Hsu, L. (2011). Effective Antibiotics in Combination against Extreme Drug-Resistant *Pseudomonas aeruginosa* with Decreased Susceptibility to Polymyxin B. *PLoS. ONE*, 6:28177.
31. Gallego, L. and Towner, K.J. (2001). Carriage of class 1 integrons and antibiotic resistance in clinical isolates of *Acinetobacter baumannii* from northern Spain. *J. Med. Microbiol.*, 50:71-77.
32. Nemeč, A.; Dolzani, L.; Brisse, S.; van den Broek, P. and Dijkshoorn, L. (2004). Diversity of aminoglycoside-resistance genes and their association with class 1 integrons among strains of pan-European *Acinetobacter baumannii* clones. *J. Med. Microbiol.*, 53:1233-1240.
33. Shaw, K.J.; Rather, P.N.; Hare, R.S. and Miller, G.H. (1993) Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. *Microbiol. Rev.*, 57:138-163.
34. Haldorsen, B.C. (2011). Aminoglycoside resistance in clinical Gram-negative isolates from Norway. M.Sc. thesis, in medical biology, Norway university of Tromsø.
35. Enwuru, N.V.; Enwuru, C.A.; Ogbonnia, S.O.; and Adepoju-Bello, A.A. (2011). Metallo-B-Lactamase Production by *Escherichia coli* and *Klebsiella* Species Isolated from Hospital and Community Subjects in Lagos, Nigeria. *Nature and Science*, 9:1-5.
36. Zacharczuk, K.; Piekarska, K.; Szych, J.; Zawidzka, E.; Sulikowska, A. and Wardak, S. (2011). Emergence of *Klebsiella pneumoniae* Coproducing KPC-2 and 16S rRNA Methylase *ArmA* in Poland. *Antimicrob Agents Chemother.*, 55:443-446.
37. Nasehi, L.; Shahcheraghi, F.; Nikbin, V.S. and Nematzadeh, S. (2010). PER, CTX-M, TEM and SHV Beta-lactamases in Clinical Isolates of *Klebsiella pneumoniae* Isolated from Tehran, Iran *IJBMS*, 13:111-118.
38. Tijet, N.; Andres, P.; Chung, C.; Lucero, C.; Low, D.E. and Galas, M. (2011). *rmtD2*, a New Allele of a 16S rRNA Methylase Gene, Has Been Present in Enterobacteriaceae Isolates from Argentina for More than a Decade. *Antimicrob. Agents Chemother.*, 55:904-909.
39. Al-kadmy, I.M. and Al-jubori, S.S. (2013). Distribution of Aminoglycoside Resistance Mediated by 16S rRNA Methylation among IraqI Isolates of *Escherichia coli* and *Pseudomonas aeruginosa*. *Agriculture and Healthcare*, 3:113-126.
40. Wassef, M. A.; El-sherif, R.H.; El-shenoufy, A.E. and Ghaith, D.M. (2010). Phenotypic and Genotype Patterns of Aminoglycoside Resistance in Gram-negative bacilli. *Journal of American Science*, 6:781-786.